Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
Pacher
Pál
P
D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy*; D002186:Cannabinoids / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D006331:Heart Diseases / Q000188:drug therapy*; D006801:Humans; D008659:Metabolic Diseases / Q000188:drug therapy*; D051379:Mice; D018345:Mice, Knockout; D009765:Obesity / Q000188:drug therapy*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D011973:Receptors, LDL / Q000172:deficiency; D000077285:Rimonabant; D015430:Weight Gain / Q000187:drug effects
D002186:Cannabinoids; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D011973:Receptors, LDL; D000077285:Rimonabant